Protocol Ledger

NCT07562152 · Phase III · RECRUITING

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Interventional Phase III clinical trial protocol NCT07562152 sponsored by Immuneering in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-05 Enrollment: 570 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07562152
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)570 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07562152
Protocol FieldVerified Registry Value
NCT IdentifierNCT07562152
Consolidated Lead SponsorImmuneering
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment570 participants (ESTIMATED)
Registered Start Date2026-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI